Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one.

The upcoming winter months bring with them the annual cold and flu season—as well as “cuffing season” for singles everywhere.

With Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc ...

MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

In addition to Nucleus’ facility at the Mayo Clinic in Rochester, Minnesota, these sites will bring radiopharmaceutical ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

Following a series of layoff rounds this year, Takeda is once again pruning its headcount in the Bay State. | As part of a ...